Table 2.
Immune cell-engagers in clinical stages.
| Name | Targets | Developer | Format | Highest Phase | Clinical Trials |
|---|---|---|---|---|---|
| AFM13 | CD30 × CD16A | Affimed GmbH | Fv + (Fv)2 + Fv, 2 + 2 TandAb |
II |
NCT04074746 and 5 studies |
| AFM24 | EGFR × CD16A | Affimed GmbH | Fv + (Fv)2 + Fv, 2 + 2 TandAb |
I/II | NCT04259450 |
| AFM26, RO7297089 |
BCMA × CD16A | Affimed GmbH, Genentech |
Fv + (Fv)2 + Fv, 2 + 2 TandAb |
I | NCT04434469 |
| Solitomab, AMG110, MT110 |
EpCAM × CD3 | Amgen | scFv + scFv, 1 + 1 BiTE |
I | NCT00635596 |
| AMG160 | PSMA × CD3 | Amgen | scFv + scFv + Fc, 1 + 1 HLE BiTE |
I |
NCT03792841 NCT04631601 |
| AMG199 | MUC17 × CD3 | Amgen | scFv + scFv + Fc, 1 + 1 HLE BiTE |
I | NCT04117958 |
| AMG330 | CD33 × CD3 | Amgen | scFv + scFv, 1 + 1 BiTE |
I |
NCT02520427 NCT04478695 |
| AMG427 | FLT3 × CD3 | Amgen | scFv + scFv + Fc, 1 + 1 HLE BiTE |
I | NCT03541369 |
| AMG562 | CD19 × CD3 | Amgen | scFv + scFv, 1 + 1 BiTE |
I | NCT03571828 |
| AMG596 | EGFRvIII × CD3 | Amgen | scFv + scFv, 1 + 1 BiTE |
I | NCT03296696 |
| AMG673 | CD33 × CD3 | Amgen | scFv + scFv + Fc, 1+ 1 HLE BiTE |
I | NCT03224819 |
| Pavurutamab, AMG701 |
BCMA × CD3 | Amgen | scFv + scFv + Fc, 1 + 1 HLE BiTE |
I | NCT03287908 |
| AMG757 | DLL3 × CD3 | Amgen | scFv + scFv + Fc, 1 + 1 HLE BiTE |
I | NCT03541369 |
| AMG910 | CLDN18.2 × CD3 | Amgen | scFv + scFv + Fc, 1 + 1 HLE BiTE |
I | NCT04260191 |
| Pasotuxizumab, AMG212, BAY2010112 |
PSMA × CD3 | Amgen, Bayer AG | scFv + scFv, 1 + 1 BiTE |
I | NCT01723475 |
| AMG420, BI836909 |
BCMA × CD3 | Amgen, Boehringer Ingelheim |
scFv + scFv, 1 + 1 BiTE |
I | NCT03836053 |
| AMG424 | CD38 × CD3 | Amgen, Xencor | Fab + scFv + Fc, 1 + 1 XmAb |
I | NCT03445663 |
| AMG509 | STEAP1 × CD3 | Amgen, Xencor | (Fab)2 + scFv + Fc, 2 + 1 XmAb |
I | NCT04221542 |
| AMV564 | CD33 × CD3 | Amphivena Therapeutics | Fv + (Fv)2 + Fv, 2 + 2 TandAb |
I | NCT04128423 and 2 studies |
| APVO436 | CD123 × CD3 | Aptevo Therapeutics | (scFv)2 + (scFv)2 + Fc, 2 + 2 ADAPTIR |
I | NCT03647800 |
| CC-93269, EM801 |
BCMA × CD3 | Celgene | Fab + (Fab)2 + Fc, 2 + 1 CrossMAb |
I | NCT03486067 |
| ERY974 | Glypican-3 × CD3 | Chugai Pharmaceutical | Fab + Fab + Fc, 1 + 1 ART-Ig |
I | NCT02748837 |
| A-319 | CD19 × CD3 | Evive Biotech | scFv + Fab, 1 + 1 | I | NCT04056975 |
| GEM333 | CD33 × CD3 | GEMoaB Monoclonals | scFv + scFv, 1 + 1 | I | NCT03516760 |
| GEM3PSCA | PSCA × CD3 | GEMoaB Monoclonals | scFv + scFv, 1 + 1 | I | NCT03927573 |
| RG6160, RO7187797, BFCR4350A |
FcRH5 × CD3 | Genentech | Fab + Fab + Fc, 1 + 1 | I | NCT03275103 |
| RG6194, BTRC4017A |
HER2 × CD3 | Genentech | undisclosed | I | NCT03448042 |
| RG6296, RO7297089 |
BCMA × CD16A | Genentech | Fab + Fab + Fc, 1 + 1 | I | NCT04434469 |
| Mosunetuzumab, RG7828, RO7030816, BTCT4465A |
CD20 × CD3 | Genentech, Roche, Chugai | Fab + Fab + Fc, 1 + 1 | II | NCT03677154 and 8 studies |
| GEN1044 | 5T4 × CD3 | Genmab, Abbvie | Fab + Fab + Fc, 1 + 1 DuoBody |
I | NCT04424641 |
| Epcoritamab, GEN3013 |
CD20 × CD3 | Genmab, Abbvie | Fab + Fab + Fc, 1 + 1 DuoBody |
III | NCT03625037 and 5 studies |
| GTB-3550, OXS-3550 |
CD33 × CD16, IL-15 | GT Biopharma | scFv + ligand + scFv, 1 + 1 + 1 TriKE |
I/II | NCT03214666 |
| HPN424 | PSMA × HSA × CD3 | Harpoon Therapeutics | sdAb + sdAb + scFv, 1 + 1 + 1 TriTAC |
I/II | NCT03577028 |
| ISB1302, GBR1302 |
HER2 × CD3 | Ichnos Sciences, Glenmark Pharmaceuticals | Fab + scFv + Fc, 1 + 1 BEAT |
I/II |
NCT02829372 NCT03983395 |
| ISB1342, GBR1342 |
CD38 × CD3 | Ichnos Sciences, Glenmark Pharmaceuticals | Fab + scFv + Fc, 1 + 1 BEAT |
I/II | NCT03309111 |
| IGM-2323 | CD20 × CD3 | IGM Biosciences | IgM + scFv, 10 + 1 | I | NCT04082936 |
| Tebentafusp, IMCgp100 |
gp100/HLA-A * 02:01 × CD3 | Immunocore | TCR + scFv, 1 + 1 ImmTAC |
III | NCT03070392 and 5 studies |
| IMC-F106C | PRAME/HLA-A * 02:01 × CD3 | Immunocore | TCR + scFv, 1 + 1 ImmTAC |
I/II | NCT04262466 |
| IMC-C103C | MAGE-A4/HLA-A * 02:01 × CD3 | Immunocore, Genentech |
TCR + scFv, 1 + 1 ImmTAC |
I/II | NCT03973333 |
| IMCnyeso, GSK01 |
NY-ESO-1/HLA-A * 02:01 × CD3 | Immunocore, GlaxoSmithKline |
TCR + scFv, 1 + 1 ImmTAC |
I/II | NCT03515551 |
| JNJ-63709178 | CD123 × CD3 | Janssen Research & Development | Fab + Fab + Fc, 1 + 1 DuoBody |
I | NCT02715011 |
| JNJ-63898081 | PSMA × CD3 | Janssen Research & Development | Fab + Fab + Fc, 1 + 1 DuoBody |
I | NCT03926013 |
| Teclistamab, JNJ-64007957 |
BCMA × CD3 | Janssen Research & Development | Fab + Fab + Fc, 1 + 1 DuoBody |
II | NCT04557098 and 5 studies |
| Talquetamab, JNJ-64407564 |
GPRC5D × CD3 | Janssen Research & Development | Fab + Fab + Fc, 1 + 1 DuoBody |
II | NCT04634552 and 3 studies |
| JNJ-67571244 | CD33 × CD3 | Janssen Research & Development | Fab + Fab + Fc, 1 + 1 DuoBody |
I | NCT03915379 |
| MGD007 | gpA33 × CD3 | MacroGenics | Fv + Fv + Fc, 1 + 1 DART-Fc |
I |
NCT02248805 NCT03531632 |
| Orlotamab, MGD009 |
B7-H3 × CD3 | MacroGenics | Fv + Fv + Fc, 1 + 1 DART-Fc |
I |
NCT02628535 NCT03406949 |
| Duvortuxizumab, MGD011, JNJ-64052781 |
CD19 × CD3 | MacroGenics, Janssen Research & Development | Fv + Fv, 1 + 1 DART |
I |
NCT02743546 NCT02454270 |
| Flotetuzumab, MGD006, S80880 |
CD123 × CD3 | MacroGenics, Servier | Fv + Fv, 1 + 1 DART |
I | NCT04582864 and 5 studies |
| Tepoditamab, MCLA-117 |
CLEC12A × CD3 | Merus | Fab + Fab + Fc, 1 + 1 Biclonics |
I | NCT03038230 |
| PF-06671008 | P-cadherin × CD3 | Pfizer | Fv + Fv + Fc, 1 + 1 DART-Fc |
I | NCT02659631 |
| PF-06863135 | BCMA × CD3 | Pfizer | Fab + Fab + Fc, 1 + 1 | II | NCT04649359 and 2 studies |
| Odronextamab, REGN1979 |
CD20 × CD3 | Regeneron | Fab + Fab + Fc, 1 + 1 | II | NCT03888105 and 2 studies |
| REGN5458 | BCMA × CD3 | Regeneron | Fab + Fab + Fc, 1 + 1 | I/II | NCT03761108 |
| REGN5459 | BCMA × CD3 | Regeneron | Fab + Fab + Fc, 1 + 1 | I | NCT04083534 |
| REGN4018 | MUC16 × CD3 | Regeneron, Sanofi | Fab + Fab + Fc, 1 + 1 | I/II |
NCT03564340 NCT04590326 |
| Glofitamab, RO7082859, RG6026 |
CD20 × CD3 | Roche | Fab + (Fab)2 + Fc, 2 + 1 CrossMAb |
III | NCT03075696 and 8 studies |
| Cibisatamab, RO6958688, RG7802 |
CEA × CD3 | Roche, Genentech | Fab + (Fab)2 + Fc, 2 + 1 CrossMAb |
I | NCT02650713 and 3 studies |
| SAR440234 | CD123 × CD3 | Sanofi | Fab + Fv + Fc, 1 + 1 | I/II | NCT03594955 |
| TNB-383B | BCMA × CD3 | TeneoBio, AbbVie | sdAb + Fab + Fc, 1 + 1 | I | NCT03933735 |
| M802 | HER2 × CD3 | Wuhan YZY Biopharma | Fab + scFv + Fc, 1 + 1 YBODY |
I | NCT04501770 |
| Plamotamab, Xmab13676 |
CD20 × CD3 | Xencor | Fab + scFv + Fc, 1 + 1 XmAb |
I | NCT02924402 |
| Tidutamab, Xmab18087 |
SSTR2 × CD3 | Xencor | Fab + scFv + Fc, 1 + 1 XmAb |
I/II |
NCT03411915 NCT04590781 |
| Vibecotamab, Xmab14045 |
CD123 × CD3 | Xencor, Novartis | Fab + scFv + Fc, 1 + 1 XmAb |
I | NCT02730312 |
| Nivatrotamab | GD2 × CD3 | Y-mAbs | IgG + (scFv)2, 2 + 2 BiClone |
I/II | NCT04750239 |